...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Veterinary Dermatology >Serum canine thymus and activation-regulated chemokine (TARC/CCL17) concentrations correlate with disease severity and therapeutic responses in dogs with atopic dermatitis
【24h】

Serum canine thymus and activation-regulated chemokine (TARC/CCL17) concentrations correlate with disease severity and therapeutic responses in dogs with atopic dermatitis

机译：血清犬胸腺和活化调节的趋化因子（Tarc / CCl17）浓度与患有特应性皮炎的狗的疾病严重程度和治疗反应相关

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Thymus and activation-regulated chemokine (TARC/CCL17) has been implicated in the pathogenesis of canine atopic dermatitis (cAD). Serum TARC concentrations are a reliable biomarker for human atopic dermatitis; however, their potential as a biomarker for cAD has not been investigated. Hypothesis/Objectives To investigate whether serum TARC concentrations correlate with disease severity and therapeutic responses for cAD. Animals Thirty-nine dogs with cAD and 42 healthy dogs were recruited. Methods and materials Serum TARC concentrations in dogs with cAD and healthy dogs were measured by sandwich ELISA with anti-canine TARC antibodies. The clinical severity of cAD was scored using the validated Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04). Serum TARC concentrations were compared between dogs with cAD and healthy controls, and their relationship with CADESI-04 was examined. Serum TARC concentrations also were measured in 20 dogs with cAD treated with prednisolone or oclacitinib for four weeks. Results Serum TARC concentrations were significantly higher in dogs with cAD than in healthy dogs (P < 0.001). In dogs with cAD, serum TARC concentrations correlated with CADESI-04 scores (rho = 0.457,P < 0.01). Furthermore, serum TARC concentrations significantly decreased in treated dogs with the attenuation of clinical signs (P < 0.001). Changes in serum TARC concentrations before and after treatment correlated with those in CADESI-04 scores (rho = 0.746,P < 0.001). Conclusions and clinical relevance Serum TARC concentrations have potential as a clinical and research tool for the objective evaluation of disease severity and therapeutic responses for cAD.
机译：背景技术胸腺和活化调节的趋化因子（Tarc / Ccl17）涉及犬的病理发生皮炎（CAD）。血清Tarc浓度是人类特性皮炎的可靠生物标志物;然而，他们作为CAD的生物标志物的潜力尚未得到调查。假设/目的探讨血清TARC浓度是否与CAD的疾病严重程度和治疗反应相关。招募了39只患有CAD和42只健康狗的动物。使用抗甘氨酸Tarc抗体，通过夹心ELISA测量与CAD和健康犬的狗中血清TARC浓度的方法和材料血清TARC浓度。 CAD的临床严重程度使用验证的犬特应性皮炎和严重程度指数，第4次迭代（CADESI-04）进行得分。在具有CAD和健康对照的狗之间比较血清TARC浓度，检查它们与CADESI-04的关系进行了检查。血清TARC浓度也以20只狗用CAD用泼尼松龙或oclacitinib处理4周。结果CAD血清TARC浓度明显高于健康犬（P <0.001）。在具有CAD的狗中，血清TARC浓度与CADESI-04分数相关（RHO = 0.457，P <0.01）。此外，治疗犬血清Tarc浓度随着临床症状的衰减而显着降低（P <0.001）。治疗前后血清TARC浓度的变化与CADESI-04分数中的那些（RHO = 0.746，P <0.001）相关。结论和临床相关性血清Tarc浓度具有临床和研究工具，用于客观评估疾病严重程度和CAD治疗反应。

著录项

  • 来源
    《Veterinary Dermatology》 |2020年第6期|共10页
  • 作者

    Asahina Ryota; Ueda Kazunori; Oshima Yuri; Kanei Toshitaka; Kato Masahiro; Furue Masutaka; Tsukui Toshihiro; Nagata Masahiko; Maeda Sadatoshi;

  • 作者单位

    Gifu Univ Fac Appl Biol Sci Dept Vet Med 1-1 Yanagido Gifu 5011193 Japan;

    Yokohama Yamate Dog &

    Cat Med Ctr Naka Ku 27-4 Kashiwaba Yokohama Kanagawa 2310866 Japan;

    Dermatol Serv Dogs &

    Cats Koto Ku TANDEM Hirano Bld 1F 2-11-14 Hirano Tokyo 1350023 Japan;

    Gifu Univ Fac Appl Biol Sci Dept Vet Med 1-1 Yanagido Gifu 5011193 Japan;

    Nippon Zenyaku Kogyo Co Ltd Anim Life Sci Labs 1-1 Tairanoue Sasagawa Asaka Machi Koriyama Fukushima 9630196 Japan;

    Kyushu Univ Grad Sch Med Sci Dept Dermatol Higashi Ku 3-1-1 Maidashi Fukuoka 8128582 Japan;

    Nippon Zenyaku Kogyo Co Ltd Anim Life Sci Labs 1-1 Tairanoue Sasagawa Asaka Machi Koriyama Fukushima 9630196 Japan;

    Vet Specialists Emergency Ctr Dermatol Serv 815 Ishigami Kawaguchi Saitama 3330823 Japan;

    Gifu Univ Fac Appl Biol Sci Dept Vet Med 1-1 Yanagido Gifu 5011193 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 皮肤病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号